Regulatory Blog

Artificial Intelligence (AI) is rapidly transforming drug development by enabling more efficient data analysis, predictive modelling, and evidence-based decision-making. Early-phase clinical trials, particularly Phase 1 studies, represent one of the most challenging stages of drug development due to uncertainties surrounding dose selection, patient recruitment, safety monitoring, and progression decisions. Improving the efficiency of these trials has the potential to accelera

Marketing Authorisations (MAs) require updates throughout a medicine's lifecycle to reflect changes in manufacturing, quality, safety, efficacy, product information, or administrative details. To ensure that these changes are appropriately assessed and approved while maintaining product quality and patient safety, the Medicines and Healthcare products Regulatory Agency (MHRA) provides detailed guidance on applying for variations to UK Marketing Authorisations. The MHRA guidan

Medicines labelling and packaging are fundamental to the safe and effective use of medicines. Clear packaging enables patients, carers, pharmacists, and healthcare professionals to correctly identify medicines, understand essential safety information, and minimise the risk of medication errors. Poor label design, confusing layouts, or lookalike packaging can contribute to dispensing mistakes and inappropriate medicine use. To promote consistent and patient-focused packaging,